The Diabetic Macular Edema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Diabetic Macular Edema Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Macular Edema Market.

Some of the key takeaways from the Diabetic Macular Edema Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Diabetic Macular Edema treatment therapies with a considerable amount of success over the years. 

• Diabetic Macular Edema companies working in the treatment market are Eluminex BioSciences, Ocugen, Innovent biologics, Curacle, GlaxoSmithKline, Exonate Limited, Ocuphire Pharma,  Unity Biotechnology, Allgenesis Biotherapeutics Inc., Mylan, Kodiak Sciences, Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Oxurion, Novartis, YD Life Science, Allegro, Opthalmics/Bausch Health, Clearside Biomedical, KalVista Pharmaceuticals, and others, are developing therapies for the Diabetic Macular Edema treatment 

• Emerging Diabetic Macular Edema therapies in the different phases of clinical trials are- EB-102, OCU200, IBI324, CU06-1004, GSK-2798745, EXN407, APX3330, UBX1325, AG-73305, MYL-1701P, KSI-301, BEOVU (RTH258; brolucizumab), VABYSMO (faricimab), KSI-301, ADVM-022, GB-102, THR-149, LKA651, YD-312, Luminate (ALG-1001, Risuteganib), Xipere (CLS-TA), KVD001, and others are expected to have a significant impact on the Diabetic Macular Edema market in the coming years.   

• In January 2024, EyePoint Pharmaceuticals has commenced the Phase II VERONA clinical trial for EYP-1901, a prospective remedy for diabetic macular edema (DME). The initial participant has been administered a dosage in the research, which aims to assess the treatment’s effectiveness in individuals previously subjected to standard anti-vascular endothelial growth factor (VEGF) therapy.

• In February 2022, Kodiak Sciences Inc. has reported the successful enrollment completion in its GLEAM and GLIMMER Phase 3 clinical trials for KSI-301, an anti-VEGF antibody biopolymer conjugate, designed for individuals with diabetic macular edema. Both studies have a primary endpoint set at one year, and participants will undergo treatment and monitoring for a duration of two years.

Diabetic Macular Edema Overview

Diabetic Macular Edema (DME) is a complication of diabetes that affects the eyes. It occurs when the macula, which is the central part of the retina responsible for sharp, central vision, swells due to the accumulation of fluid. DME is a type of diabetic retinopathy, a condition that can affect individuals with diabetes.

Get a Free Sample PDF Report to know more about Diabetic Macular Edema Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-pipeline-insight

Emerging Diabetic Macular Edema Drugs Under Different Phases of Clinical Development Include:

• EB-102: Eluminex BioSciences

• OCU200: Ocugen

• IBI324: Innovent biologics

• CU06-1004: Curacle

• GSK-2798745: GlaxoSmithKline

• EXN407: Exonate Limited

• APX3330: Ocuphire Pharma

• UBX1325: Unity Biotechnology

• AG-73305: Allgenesis Biotherapeutics Inc.

• MYL-1701P: Mylan

• KSI-301: Kodiak Sciences

• BEOVU (RTH258; brolucizumab): Novartis

• VABYSMO (faricimab): Roche

• KSI-301: Kodiak Sciences

• ADVM-022: Adverum Biotechnologies

• GB-102: Graybug Vision

• THR-149: Oxurion

• LKA651: Novartis

• YD-312: YD Life Science

• Luminate (ALG-1001, Risuteganib): Allegro Opthalmics/Bausch Health

• Xipere (CLS-TA): Clearside Biomedical

• KVD001: KalVista Pharmaceuticals 

Diabetic Macular Edema Pipeline Therapeutics Assessment

• Diabetic Macular Edema Assessment by Product Type

• Diabetic Macular Edema By Stage and Product Type

• Diabetic Macular Edema Assessment by Route of Administration

• Diabetic Macular Edema By Stage and Route of Administration

• Diabetic Macular Edema Assessment by Molecule Type

• Diabetic Macular Edema by Stage and Molecule Type

DelveInsight’s Diabetic Macular Edema Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Diabetic Macular Edema product details are provided in the report. Download the Diabetic Macular Edema pipeline report to learn more about the emerging Diabetic Macular Edema therapies

Some of the key companies in the Diabetic Macular Edema Therapeutics Market include:

Key companies developing therapies for Diabetic Macular Edema are – Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotechnology, Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Allegro Opthalmics, Bausch Health, Clearside Biomedical, KalVista Pharmaceuticals, and others.

Diabetic Macular Edema Pipeline Analysis:

The Diabetic Macular Edema pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Macular Edema with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Macular Edema Treatment.

• Diabetic Macular Edema key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Diabetic Macular Edema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Macular Edema market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diabetic Macular Edema drugs and therapies

Diabetic Macular Edema Pipeline Market Drivers

• Growing Prevalence of diabetes, development of novel therapies, investment in Research and Development activities are some of the important factors that are fueling the Diabetic Macular Edema Market.

Diabetic Macular Edema Pipeline Market Barriers

• However, high medical cost, lack of approved therapies and other factors are creating obstacles in the Diabetic Macular Edema Market growth.

Scope of Diabetic Macular Edema Pipeline Drug Insight    

• Coverage: Global

• Key Diabetic Macular Edema Companies: Eluminex BioSciences, Ocugen, Innovent biologics, Curacle, GlaxoSmithKline, Exonate Limited, Ocuphire Pharma,  Unity Biotechnology, Allgenesis Biotherapeutics Inc., Mylan, Kodiak Sciences, Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Oxurion, Novartis, YD Life Science, Allegro, Opthalmics/Bausch Health, Clearside Biomedical, KalVista Pharmaceuticals, and others

• Key Diabetic Macular Edema Therapies: EB-102, OCU200, IBI324, CU06-1004, GSK-2798745, EXN407, APX3330, UBX1325, AG-73305, MYL-1701P, KSI-301, BEOVU (RTH258; brolucizumab), VABYSMO (faricimab), KSI-301, ADVM-022, GB-102, THR-149, LKA651, YD-312, Luminate (ALG-1001, Risuteganib), Xipere (CLS-TA), KVD001, and others

• Diabetic Macular Edema Therapeutic Assessment: Diabetic Macular Edema current marketed and Diabetic Macular Edema emerging therapies

• Diabetic Macular Edema Market Dynamics: Diabetic Macular Edema market drivers and Diabetic Macular Edema market barriers 

Request for Sample PDF Report for Diabetic Macular Edema Pipeline Assessment and clinical trials

Table of Contents

1. Diabetic Macular Edema Report Introduction

2. Diabetic Macular Edema Executive Summary

3. Diabetic Macular Edema Overview

4. Diabetic Macular Edema- Analytical Perspective In-depth Commercial Assessment

5. Diabetic Macular Edema Pipeline Therapeutics

6. Diabetic Macular Edema Late Stage Products (Phase II/III)

7. Diabetic Macular Edema Mid Stage Products (Phase II)

8. Diabetic Macular Edema Early Stage Products (Phase I)

9. Diabetic Macular Edema Preclinical Stage Products

10. Diabetic Macular Edema Therapeutics Assessment

11. Diabetic Macular Edema Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diabetic Macular Edema Key Companies

14. Diabetic Macular Edema Key Products

15. Diabetic Macular Edema Unmet Needs

16 . Diabetic Macular Edema Market Drivers and Barriers

17. Diabetic Macular Edema Future Perspectives and Conclusion

18. Diabetic Macular Edema Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/